Advertisement

Die Anwendung von Botulinumtoxin in der HNO-Heilkunde

  • S. Rohrbach
  • R. Laskawi
Chapter
  • 678 Downloads
Part of the HNO Praxis heute book series (HNO, volume 24)

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Kerner J (1817) Vergiftung durch verdorbene Würste. Tübinger Blätter für Naturwissenschaften und Arzneykunde 3: 1–25Google Scholar
  2. 2.
    Kerner J (1822) Das Fettgift oder die Fettsäure und ihre Wirkungen auf den thierischen Organismus, ein Beytrag zur Untersuchung des in verdorbenen Würsten giftig wirkenden Stoffes. Cotta Stuttgart, TübingenGoogle Scholar
  3. 3.
    Van Ermengem EP (1897) Über einen neuen anaeroben Bacillus und seine Beziehung zum Botulismus. Z Hyg Infektionskrankh 26: 1–56Google Scholar
  4. 4.
    Scott AB (1979) An alternative to strabismus surgery. Transactions of the 4th Int Orthoptic Congress, Bern 24–25Google Scholar
  5. 5.
    Scott AB, Rosenbaum A, Collins CC (1973) Pharmacological weakening of extraocular muscles. Invest Ophthalmol 12: 924–927PubMedGoogle Scholar
  6. 6.
    Neale EA, Bowers LM, Jia M, Bateman KE, Williamson LC (1999) Botulinum neurotoxin A blocks synaptic vesicle exocytosis but not endocytosis at the nerve terminal. J Cell Biol 147: 1249–1260CrossRefPubMedGoogle Scholar
  7. 7.
    Osen Sand A, Staple JK, Naldi E, Schiavo G, Rossetto O, Petitpierre S, Malgaroli A, Montecucco C, Catsicas S (1996) Common and distinct fusion proteins in axonal growth and transmitter release. J Comp Neurol 367: 222–234PubMedGoogle Scholar
  8. 8.
    Naumann M, Jost WH, Toyka KV (1999) Botulinum toxin in the treatment of neurological disorders of the autonomic nervous system. Arch Neurol 56: 914–916CrossRefPubMedGoogle Scholar
  9. 9.
    Laskawi R (1998) Die therapeutische Anwendung von Botulinum-Toxin im Hals-Nasen-Ohren-Bereich. Teil 1: Die Behandlung von Bewegungsstörungen der mimischen Muskulatur. HNO 46: 281–287PubMedGoogle Scholar
  10. 10.
    Hallett M, Glocker F, Deutschl G (1994) Mechanism of action of botulinum toxin. Ann Neurol 36: 449–450CrossRefPubMedGoogle Scholar
  11. 11.
    Lang DJ, Brin MF, Warner CL, Fahn S, Lovelace RE (1987) Distant effects of local injections of botulinum toxin. Muscle Nerve 10: 552–555Google Scholar
  12. 12.
    Olney RK, Aminoff MJ, Gelb DJ, Lowenstein DH (1988) Neuromuscular effects distant from the site of botulinum neurotoxin injection. Neurology 38: 1780–1783PubMedGoogle Scholar
  13. 13.
    Wiegand H, Erdmann G, Wellhoner HH (1976). 125 Labelled botulinum A neurotoxin: pharmacokinetics in cats after intramuscular injection. Naunyn-Schmiedebergs Arch Pharmacol 292: 161–165PubMedGoogle Scholar
  14. 14.
    Garner CG, Straube A, Witt TN, Gasser T, Oertel WH (1993) Time course of distant effects of local injections of botulinum toxin. Mov Disord 8: 33–37CrossRefPubMedGoogle Scholar
  15. 15.
    Simpson LL (1989) Peripheral actions of the botulinum neurotoxins. Botulinum Neurotoxin and Tetanus Toxin. San Diego, CA: Academic Press 153–178Google Scholar
  16. 16.
    Pamphlett R (1989) Early terminal and nodal sprouting of motor axons after botulinum toxin. J Neurol Sci 92: 181–192CrossRefPubMedGoogle Scholar
  17. 17.
    Holland RL, Brown MC (1981) Nerve growth in botulinum toxin poisoned muscles. Neuroscience 6: 1167–1179CrossRefPubMedGoogle Scholar
  18. 18.
    Duchen LW, Strich T (1968) The effects of botulinum toxin on the pattern of innervation of skeletal muscle in the mouse. QJ Exp Physio 53: 84–89Google Scholar
  19. 19.
    Laskawi R, Ellies M, Drobik C, Bätz A (1994) Botulinum toxin treatment in patients with hemifacial spasm. Eur Arch Otorhinolaryngol 251: 271–274CrossRefPubMedGoogle Scholar
  20. 20.
    Laskawi R (1997) Combination of hypoglossal-facial nerve anastomosis and botulinum toxin injections to optimize mimic rehabilitation after removal of acoustic neurinoma. Plast Reconstr Surg 99: 1006–1011PubMedGoogle Scholar
  21. 21.
    Kessler K, Skutta M, Benecke R (1999) Long-term treatment of cervical dystonia with botulinum toxin A. Efficacy, safety, and antibody frequency. J Neurol 246: 265–274CrossRefPubMedGoogle Scholar
  22. 22.
    Duane C, Clark M, LaPointe L, Case JLMD (1995) Botulinum toxin A antibodies in initial and delayed restistance to botulinum toxin A therapy in cervical dystonia. Mov Disord 10: 394Google Scholar
  23. 23.
    Hanna P, Jankovic J (1998) Mouse bioassay versus Western blot assay for botulinum toxin antibodies. Neurology 50: 1624–1629PubMedGoogle Scholar
  24. 24.
    Birklein F, Erbguth M (2000) Sudomotor or sweating test for Bt antibodies. Mov Disord 15: 146–147CrossRefPubMedGoogle Scholar
  25. 25.
    Alderson K, Holds JB, Anderson RL (1991) Botulinum-induced alterations of nerve-muscle interactions in the human orbicularis oculi following treatment for blepharospasm. Neurology 41: 1800–1805PubMedGoogle Scholar
  26. 26.
    Meyer KF, Eddie B (1951) Perspectives concerning botulism. Z Hyg Infektionskrankh 133: 255–263Google Scholar
  27. 27.
    Schantz EJ, Sugiyama H (1974) Toxic proteins produced by Clostridium botulinum. J Agr Food Chem 22: 26–30CrossRefGoogle Scholar
  28. 28.
    Tsui JKC, O’Brien CF (1994) Clinical trials for spasticity. In: Janacivic J (ed) Therapy with Botulinum Toxin. Marcel Dekker Inc, New York 523–533Google Scholar
  29. 29.
    Wohlfahrt K, Göschel H, Frevert J, Dangler R, Bigalke H (1997) Botulinum toxin A toxins: units versus units. Naunyn-Schmiedebergs. Arch Pharmacol 335: 335–340Google Scholar
  30. 30.
    Elston J (1993) In: Current therapy in neurologic disease. Mosby Year Book, 276–281Google Scholar
  31. 31.
    Marchese Ragona R, Blotta P, Pastore A, Tugnoli V, Eleopra R, De Grandis D (1999) Management of parotid sialocele with botulinum toxin. Laryngoscope 109: 1344–1346PubMedGoogle Scholar
  32. 32.
    Brin MF (2003) Fundamentals of dystonia. In: Moore P, Naumann M (eds) Handbook of Botulinum Toxin Treatment. 2nd edn, Blackwell Science, Massachusetts, pp. 101–118Google Scholar
  33. 33.
    Nutt JG, Muenter MD, Aronson A, Kurland LT, Melton LJ III (1988) Epidemiology of focal and generalized dystonia in Rochester. Minnesota Mov Disord 3: 188–194Google Scholar
  34. 34.
    Fahn S, Marden CD, Calne DB (1987) Classification and investigation of dystonia. In: Marsden CD, Fahn S (eds) Movement Disorders 2nd edn, Butterworths, London, pp 332–358Google Scholar
  35. 35.
    Marsden CD, Obeso JA, Zarranz JJ, Lang AE (1985) The anatomical basis of symptomatic hemidystonia. Brain 108: 463–483PubMedGoogle Scholar
  36. 36.
    Laskawi R, Roggenkämper P (2004) Botulinumtoxin-Therapie im Kopf-Hals-Bereich, 2. Aufl. Urban & Vogel, MünchenGoogle Scholar
  37. 37.
    Brin MF, Danisi F, Blitzer A (2003). Blepharospasm, oromandibular dystonia, Meige’s syndrome and hemifacial spasm. In: Moore P, Naumann M (eds) Handbook of Botulinum Toxin Treatment, 2nd edn. Blackwell Science, Massachusetts, pp 119–141Google Scholar
  38. 38.
    Boghen DR, Lesser RL (2000) Blepharospasm and hemifacial spasm. Curr Treat Options Neurol 2: 393–400PubMedGoogle Scholar
  39. 39.
    Fahn S (1988) Blepharospasmus: a form of focal dystonia. Adv Neurol 49: 125–133PubMedGoogle Scholar
  40. 40.
    Ceballos-Baumann AO (1996) Dystonien. In: Conrad B, Ceballos-Baumann AO (Hrsg) Bewegungsstörungen in der Neurologie. Thieme, StuttgartGoogle Scholar
  41. 41.
    Laskawi R, Roggenkämper P (1999) Die Behandlung von Synkinesien mit Botulinum-Toxin. In: Botulinumtoxin-Therapie im Kopf-Hals-Bereich. Urban und Vogel, München, S 82–84Google Scholar
  42. 42.
    Jannetta PJ, Abbasy M, Maroon JC, Ramos FM, Albin MS (1977) Etiology and definitive microsurgical treatment of hemifacial spasm. J Neurosurg 47: 321–328PubMedGoogle Scholar
  43. 43.
    Roggenkämper P, Nüssgens Z (1997) Frontalis suspension in the treatment of essentiell blepharospasm unresponsive to botulinum toxin therapy: Long term results. Graefe’s Arch Clin Exp Ophthalmol 235: 486–489Google Scholar
  44. 44.
    Laskawi R (2000) Botulinum-Toxin in der Behandlung von Innervationsstörungen der Hirnnerven — Eine Bestandsaufnahme. Laryngo-Rhino-Otol 79: 675–676Google Scholar
  45. 45.
    Brin MF (1992) Advances in dystonia: genetics and treatment with botulinum toxin. In: Smith B, Adelman (eds) Neuroscience Year, Supplement to the Encyclopedia of Neuroscience. Birkhauser, Boston pp 56–58Google Scholar
  46. 46.
    Laskawi R, Rohrbach S (2001) Oromandibuläre Dystonien. Laryngo-Rhino-Otol 80: 708–713Google Scholar
  47. 47.
    McKenna JA, Dedo HH (1992) Cricopharyngeal myotomy. Indications and technique. Ann Otol Rhinol Laryngol 101: 216–221PubMedGoogle Scholar
  48. 48.
    Blitzer A (1997) Cricopharyngeal muscle spasm and dysphagia. Op Tech Otolaryngol Head Neck Surg 116: 328–329Google Scholar
  49. 49.
    Pototschnig W, Thumfart WF (1999) Die Behandlung von Schluckstörungen. In: Laskawi R, Roggenkämper P (Hrsg) Botulinum-Toxin-Therapie im Kopf-Hals-Bereich. Urban & Vogel, München, S. 156–170Google Scholar
  50. 50.
    Stacy M (2000) Idiopathic cervical dystonia: an overview. Neurology 55: 2–8Google Scholar
  51. 51.
    Kessler KR, Skutta M, Benecke R (1999) Long-term treatment of cervical dystonia with botulinum toxin A. Efficacy, safety and antibody frequency. J Neurol 246: 265–274CrossRefPubMedGoogle Scholar
  52. 52.
    Factor SA, Podskalny GD, Molho ES (1995) Psychogenic movement disorders. Frequency, clinical profile and characteristics. J Neurol Neurosurg Psychiatry 59: 406–412PubMedGoogle Scholar
  53. 53.
    Wissel J, Müller J, Ebersbach G, Poewe W (1999) Trick manoeuvres in cervical dystonia: investigation of movement-and touch-related changes in polymyographic activity. Mov. Disord 14: 994–999CrossRefPubMedGoogle Scholar
  54. 54.
    Brookes GB. Laryngeal dystonia. In: Moore P (ed) Botulinum toxin treatment. Blackwell, Oxford, pp 181–205Google Scholar
  55. 55.
    Blitzer A, Brin MF, Stewart CF (1998) Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients. Laryngoscope 108: 1435–1441PubMedGoogle Scholar
  56. 56.
    Sulica L, Verheyden J, Blitzer A (2003) The larynx and pharynx In: Moore P, Naumann M (eds) Handbook of Botulinum Toxin Treatment, 2nd edn. Blackwell Science, Massachusetts, pp 142–157Google Scholar
  57. 57.
    Murry T, Woodson GE (1995) Combined-modality treatment of adductor spasmodic dysphonia with botulinum toxin and voice therapy. J Voice 9: 460–465PubMedGoogle Scholar
  58. 58.
    Nasri S, Sercarz JA, McAlpin T, Berke GS (1995) Treatment of vocal fold granuloma using botulinum toxin type A. Laryngoscope 105: 585–588PubMedGoogle Scholar
  59. 59.
    Orloff LA, Goldman SN (1999) Vocal fold granuloma:successful treatment with botulinum toxin. Otolaryngol Head Neck Surg 121: 410–413CrossRefPubMedGoogle Scholar
  60. 60.
    Nathan CO, Yin S, Stucker FJ (1999) Botulinum toxin: adjunctive treatment for posterior glottic synechiae. Laryngoscope 109: 855–857PubMedGoogle Scholar
  61. 61.
    Pototsching C, Thumfart F (1999). Behandlung des beidseitigen Stimmlippenstillstandes. In: Laskawi R, Roggenkämper P (Hrsg) Botulinumtoxin-Therapie im Kopf-Hals-Bereich. Urban & Vogel, MünchenGoogle Scholar
  62. 62.
    Drobik C, Laskawi R (1994) Fey-Syndrom: Behandlung mit Botulinum-Toxin. HNO Aktuell 2: 142–144Google Scholar
  63. 63.
    Drobik C, Laskawi R (1995) Frey’s syndrome: treatment with botulinum toxin. Acta Otolaryngol 115: 459–461PubMedGoogle Scholar
  64. 64.
    Laskawi R, Rohrbach S (2001) Teatment of gustatory sweating with botulinum toxin: Special aspects. ORL 63: 294–297CrossRefPubMedGoogle Scholar
  65. 65.
    Laskawi R, Rohrbach S (2002) Frey’s syndrome. Treatment with botulinum toxin. In: Kreyden OP, Böni R, Burg G (eds) Hyperhidrosis and botulinum toxin in dermatology. Curr Probl Dermatol. Karger, Basel, pp 170–177Google Scholar
  66. 66.
    Laskawi R, Drobik C, Schönbeck C (1998) Up-to-date report of botulinum toxin type A treatment in patients with gustatory sweating (Frey’s syndrome). Laryngoscope 108: 381–384PubMedGoogle Scholar
  67. 67.
    Ellies M, Laskawi R, Rohrbach-Volland S, Arglebe C, Beuche W (2002) Botulinum toxin to reduce saliva flow: Selected indications for ultrasound-guided toxin application into salivary glands. Laryngoscope 112: 82–86PubMedGoogle Scholar
  68. 68.
    Ellies M, Laskawi R, Götz W, Arglebe C, Tormählen G (1999) Immunhistochemical and morphometric investigations of the influence of botulinum toxin on the submandibular gland of the rat. Eur Arch Otorhinolaryngol 256: 148–152CrossRefPubMedGoogle Scholar
  69. 69.
    Kinkelin I, Hund M, Naumann M, Hamm H (2000) Effective treatment of frontal hyperhidrosis with botulinum toxin. Br J Dermatol 143: 824–827CrossRefPubMedGoogle Scholar
  70. 70.
    Böger A, Herath H, Rompel R, Ferbert A (2000) Botulinum toxin for treatment of craniofacial hyperhidrosis. J Neurol 415: 857–861Google Scholar
  71. 71.
    Rosales RL, Arimura K, Takenaga S, Osame M (1996) Extrafusal and intrafusal effects in experimental botulinum toxin A injections. Muscle Nerve 19: 488–496CrossRefPubMedGoogle Scholar
  72. 72.
    Giladi N (1997) The mechanism of action of botulinum toxin type A in focal dystonia is most probably through its dual effect on efferent (motor) and afferent pathways at the injected site. J Neurol Sci 152: 132–135CrossRefPubMedGoogle Scholar
  73. 73.
    Nurmikko TJ (2003) Managment of pain with botulinum toxin. In: Moore P, Naumann M (eds) Handbook of Botulinum Toxin Treatment, 2nd edn. Blackwell Science, Massachusetts pp 404–421Google Scholar
  74. 74.
    Rohrbach S, Olthoff A, Laskawi R, Götz W (2002) Neuronal nitric oxide synthase-immunoreactivity — A neuromodulating system independent of peripheral nasal gland denervation in guinea pig nasal mucosal tissue after treatment with botulinum toxin type A. ORL 64(5): 330–334CrossRefPubMedGoogle Scholar
  75. 75.
    Kim K-S, Kim S-S, Yoon J-H, Han JW (1998) The effect of botulinum toxin type A injection for intrinsic rhinitis. J Laryngol Otol 112: 248–251PubMedGoogle Scholar
  76. 76.
    Rohrbach S, Olthoff A, Laskawi R, Giefer B, Götz W (2001) Botulinum toxin type A induces apoptosis in nasal glands of guinea pigs. Ann Otol Laryngol 110: 1045–1050Google Scholar
  77. 77.
    Rohrbach S, Laskawi R (2001) Minimally invasive application of botulinum toxin type A in nasal hypersecretion. ORL 63: 382–384CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag Heidelberg 2005

Authors and Affiliations

  • S. Rohrbach
    • 1
  • R. Laskawi
    • 2
  1. 1.HNO-KlinikUniversität GöttingenGöttingenGermany
  2. 2.HNO-KlinikUniversität GöttingenGöttingenGermany

Personalised recommendations